Date: 2015-05-11
Type of information: Presentation of results at a congress
phase: 3
Announcement: presentation of results at the 17th European Congress of Endocrinology (ECE), being held in Dublin, Ireland, from May 16-20, 2015.
Company: Chiasma (USA- MA - Israel)
Product: octreotide capsules
Action
mechanism: peptide. Octreotide capsules are an investigational oral form of the peptide octreotide, a somatostatin analog that is currently available only by injection. Octreotide capsules uses a proprietary technology developed by Chiasma Inc., called Transient Permeability Enhancer (TPE®) that facilitates gastrointestinal absorption of unmodified drug into the bloodstream.
Disease: acromegaly
Therapeutic area: Hormonal diseases - Rare diseases - Endocrine diseases
Country:
Trial details:
Latest
news: * On May 11, 2015, Chiasma, Inc., a U.S. privately held biopharma company developing octreotide capsules for the orphan condition acromegaly, announced that two abstracts evaluating patients with acromegaly will be presented at the 17th European Congress of Endocrinology (ECE), being held in Dublin, Ireland, from May 16-20, 2015. Octreotide capsules are in clinical development for the treatment of acromegaly, a condition for which the current standard treatment is lifelong injections. Based on Phase III results recently published online by the Journal of Clinical Endocrinology & Metabolism, Chiasma intends to submit a New Drug Application to the FDA in mid-2015. If approved, octreotide capsules will be the first and only oral somatostatin analog approved for acromegaly. ePosters: Pituitary Basic and Neuroendocrinology EP-710: “Patient Reported Outcomes Comparing Octreotide Capsules to Somatostatin Analog Injections – Results from a Multicenter, Baseline Controlled, Phase 3 Study in Acromegaly” EP-711: “Parenteral Somatostatin Analogs: a Focus on Injection Site Adverse Reactions”
Authors: Asi Haviv, Gary Patou, Susan Mathias
Authors: Asi Haviv, William Kramer, Gary Patou
